Celgene (Nasdaq:CELG)
has been consistently profitable for a while, which is rare enough in
the biotech space. What stands out to me with Celgene, though, is that
the company has largely been riding just one drug in recent years
(Revlimid) and the contributions of newer compounds should offer some
very lucrative revenue growth over the next five to ten years. Although
the multi-year bull market in biotech has stripped away most of the
value from the sector, Celgene is operationally still a very interesting
company to watch.
Please continue here:
http://www.investopedia.com/stock-analysis/072613/celgene-only-getting-started-streets-already-looking-ahead-celg-jnj-onxx-abbv.aspx
No comments:
Post a Comment